Search

Introduction/Background To estimate the incidence of abdominal wall metastases (AWM) and their impact on overall survival in patients with advanced low-grade serous ovarian cancer (LGSOC). Methodology Patients with advanced LGSOC (FIGO stage III–IV) undergoing primary and/or secondary cytoreductive surgery at our Institution between August 2001 and August 2016 were retrospectively identified. Incidence of AWM was evaluated by review of electronic medical records. Overall survival was estimated using the Kaplan-Meier method. Results Total of 60 women who met inclusion criteria were identified. Of them, 30 (50%) patients had AWM, including 12 (20%) at primary surgery, 18 (30%) at relapse, or both 8 (13.3%). Among patients with evidence of AWM at primary surgery, 11 (91.7%) had prior surgery (10 laparoscopic, 1 laparotomy). Median follow-up was 87 (IQR 51, 127) years. Among the 60 patients, 24 (40%) died of disease [17/30 (56.7%) vs. 8/30 (26.7%) in the groups with and without AWM, respectively]. The median overall survival in the group of patients with AWM was lower than in the group without AWM (80 months; 95% CI 80–103 vs. 89 months; 95% CI 73–104, respectively, Log rank test, P=0.085), although not statistically significant. Conclusion Incidence of AWM in advanced LGSOC is high (50% in the present series) compared to high-grade serous epithelial ovarian cancer (3–5%) (Cormio et al, 2003, Gynecologic Oncology) and is associated with decreased overall survival. Disclosure Nothing to disclose.

Objectives To evaluate the impact of cervical re-injection on the detection rate of fluorescence-guided sentinel lymph node (SLN) mapping in endometrial cancer (EC) patients undergoing robotic-assisted surgical staging. Methods From April, 1 2017 to December, 31 2018 patients undergoing robotic-assisted surgery for apparently early-stage EC at our Institution were prospectively treated with SLN mapping using indocyanine green (ICG) accordingly to the Memorial Sloan Kettering Cancer Center (MSKCC) surgical algorithm. As per MSKCC algorithm, four mL (1.25 mg/mL) of ICG were injected into the cervical submucosa and stroma, at the 3 and 9 o’clock positions (1 mL each). In case of either no detection or unilateral detection, cervical re-injection was performed followings the same steps as previously described. Overall (successful mapping of at least one hemipelvis) and bilateral detection were evaluated pre- and post-re-injection. Results Of the 107 patients undergoing robotic-assisted surgical staging for EC during the study period, 7 cases with no detection or unilateral detection who did not underwent re-injection were excluded. Among the remaining 100 patients, after a single injection the overall detection rate was 98% (95% CI, 92.2–99.6%) with a 69% (95% CI, 58.8–77.7%) of bilateral detection rate. After re-injection, overall and bilateral detection rate were 100% (95% CI, 95.3–100%) and 91% (95% CI, 8.32–95.5%), respectively. Conclusions In the case of no detection or unilateral sentinel lymph node detection, cervical re-injection of ICG can increase overall and bilateral detection rate, thus decreasing the number of patients requiring a complete bilateral or side-specific lymphadenectomy.